Biocept, which develops and markets cancer diagnostic tests, raised $19 million by offering 1.9 million shares at $10, the low end of the range of $10 to $12. The company had originally filed to offer 1.8 million shares. At the IPO price, the company...read more
Six companies completed US IPOs last week, and all but one gained more than 10% in early trading. Chinese lottery service provider 500.com (WBAI) was the top performer, gaining 54% after pricing above the range. Vince (VNCE), a high-end apparel retailer, was...read more
Biocept Laboratories, which develops and markets cancer diagnostic tests, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $20 million by offering 1.8 million shares at a price range of $10 to $12. At the midpoint of the...read more
Biocept prices IPO at $10, the low end of the range
Biocept, which develops and markets cancer diagnostic tests, raised $19 million by offering 1.9 million shares at $10, the low end of the range of $10 to $12. The company had originally filed to offer 1.8 million shares. At the IPO price, the company...read more
12 US IPOs planned for the week of Feb 3
The following IPOs are expected to price this week: Argos Therapeutics (ARGS), which is developing immunotherapies for the treatment of cancer and HIV, plans to raise...read more
US IPO Recap: Chinese IPOs continue their strong run
Six companies completed US IPOs last week, and all but one gained more than 10% in early trading. Chinese lottery service provider 500.com (WBAI) was the top performer, gaining 54% after pricing above the range. Vince (VNCE), a high-end apparel retailer, was...read more
Cancer diagnostic company Biocept Laboratories sets terms for $20 million IPO
Biocept Laboratories, which develops and markets cancer diagnostic tests, announced terms for its IPO on Wednesday. The San Diego, CA-based company plans to raise $20 million by offering 1.8 million shares at a price range of $10 to $12. At the midpoint of the...read more